News
-
ADVENTRX Engages Theradex Systems, Inc. To Manage Phase 3 Clinical Study Of ANX-188
10/2/2012
ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has engaged Theradex® Systems, Inc., a contract research organization with 30 years of experience, to manage the Company's upcoming phase 3 study of ANX-188 (purified poloxamer 188) in sickle cell disease.
-
NIH Launches Trial For Rare Degenerative Muscle Disease Treatment
9/25/2012
Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.
-
Agile Therapeutics To Present At CBI's Forum On Phase II-III Clinical Study Optimization
9/20/2012
Agile Therapeutics announced today that Dr. Marie Foegh, Chief Medical Officer and Vice President of Clinical Research and Development, will be presenting at CBI's Forum on Phase II-III Clinical Study Optimization. The event takes place September 20-21, 2012 in Chicago.
-
Merck Announces New Phase III Data For Suvorexant, An Investigational Insomnia Medicine
9/10/2012
Merck, known as MSD outside the United States and Canada, recently announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.
-
Xtandi Gets Speedy FDA Ok For Metastatic Castration-Resistant Prostate Cancer
9/5/2012
In an August 31, 2012 press release, Medivation, Inc. and Astellas Pharma, Inc. announced that their highly anticipated drug Xtandi (enzalutamide) has received an unusually speedy approval from the FDA for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has failed treatment with Sanofi’s Taxotere (docetaxel). By Dr. Cheryl Strelko, GlobalData's analyst covering Oncology.
-
Novartis QVA149 Phase III Study Meets Primary Endpoint In Reducing Exacerbations In COPD Patients, Filing In EU And Japan By End Of Year
8/30/2012
Novartis announced recently that the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) Phase III study, SPARK, met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide (Seebri Breezhaler).
-
Teva To Initiate Third Phase III Trial Of Oral Laquinimod For The Treatment Of Relapsing Remitting Multiple Sclerosis
8/8/2012
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).
-
Ricerca Biosciences Launches Two New Preclinical Assay Services
7/26/2012
Ricerca Biosciences, an integrated preclinical pharmaceutical contract research organization (CRO), today announced the introduction of two new state-of-the-art cellular assay services: Early Safety Screening Cytotoxicity and ImmunoSIGNAL™ Cytokine Storm Cellular Assay.
-
Camargo Uses 505(b)(2) To Fast Track Indian Products
7/24/2012
Camargo Pharmaceutical Services successfully completed five Food and Drug Administration (FDA) pre-IND meetings for 505(b)(2) products in the month of June, including successful meetings with two of India’s top 10 largest pharmaceutical companies.
-
Titan Completes Preclinical Study Of A Continuous, Dopamine Agonist Treatment for Parkinson's Disease
7/10/2012
Titan Pharmaceuticals, Inc. (
OTCBB : TTNP) today announced that it has successfully completed investigation into the feasibility of a long-term, round-the-clock, non-fluctuating dopamine agonist treatment for Parkinson's disease. The preclinical study was primarily funded by a $495,000 grant awarded to Titan by the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) program, and administered by the National Institute of Neurological Disorders and Stroke (NINDS).